Literature DB >> 24293134

Development of purely structure-based pharmacophores for the topoisomerase I-DNA-ligand binding pocket.

Malgorzata N Drwal1, Keli Agama, Yves Pommier, Renate Griffith.   

Abstract

Purely structure-based pharmacophores (SBPs) are an alternative method to ligand-based approaches and have the advantage of describing the entire interaction capability of a binding pocket. Here, we present the development of SBPs for topoisomerase I, an anticancer target with an unusual ligand binding pocket consisting of protein and DNA atoms. Different approaches to cluster and select pharmacophore features are investigated, including hierarchical clustering and energy calculations. In addition, the performance of SBPs is evaluated retrospectively and compared to the performance of ligand- and complex-based pharmacophores. SBPs emerge as a valid method in virtual screening and a complementary approach to ligand-focussed methods. The study further reveals that the choice of pharmacophore feature clustering and selection methods has a large impact on the virtual screening hit lists. A prospective application of the SBPs in virtual screening reveals that they can be used successfully to identify novel topoisomerase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24293134      PMCID: PMC7578780          DOI: 10.1007/s10822-013-9695-x

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  33 in total

1.  Development of computational and graphical tools for analysis of movement and flexibility in large molecules.

Authors:  P A Keller; S P Leach; T T Luu; S J Titmuss; R Griffith
Journal:  J Mol Graph Model       Date:  2000-06       Impact factor: 2.518

2.  The mechanism of topoisomerase I poisoning by a camptothecin analog.

Authors:  Bart L Staker; Kathryn Hjerrild; Michael D Feese; Craig A Behnke; Alex B Burgin; Lance Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

3.  Pose prediction and virtual screening performance of GOLD scoring functions in a standardized test.

Authors:  John W Liebeschuetz; Jason C Cole; Oliver Korb
Journal:  J Comput Aided Mol Des       Date:  2012-02-28       Impact factor: 3.686

Review 4.  Three-dimensional pharmacophore methods in drug discovery.

Authors:  Andrew R Leach; Valerie J Gillet; Richard A Lewis; Robin Taylor
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

5.  Structure-Based Pharmacophores for Virtual Screening.

Authors:  Martin Löwer; Ewgenij Proschak
Journal:  Mol Inform       Date:  2011-05-04       Impact factor: 3.353

Review 6.  Topoisomerase I inhibitors: camptothecins and beyond.

Authors:  Yves Pommier
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

7.  Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.

Authors:  Bart L Staker; Michael D Feese; Mark Cushman; Yves Pommier; David Zembower; Lance Stewart; Alex B Burgin
Journal:  J Med Chem       Date:  2005-04-07       Impact factor: 7.446

8.  A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone.

Authors:  Hong Liang; Xing Wu; Lynn J Guziec; Frank S Guziec; Kimberly K Larson; Jennifer Lang; Jack C Yalowich; Brian B Hasinoff
Journal:  J Chem Inf Model       Date:  2006 Jul-Aug       Impact factor: 4.956

9.  Apoptosis induction and cell cycle perturbation in human hepatoma hep G2 cells by 10-hydroxycamptothecin.

Authors:  X W Zhang; C Qing; B Xu
Journal:  Anticancer Drugs       Date:  1999-07       Impact factor: 2.248

10.  Rationalizing tight ligand binding through cooperative interaction networks.

Authors:  Bernd Kuhn; Julian E Fuchs; Michael Reutlinger; Martin Stahl; Neil R Taylor
Journal:  J Chem Inf Model       Date:  2011-12-09       Impact factor: 4.956

View more
  5 in total

1.  Ensemble pharmacophore meets ensemble docking: a novel screening strategy for the identification of RIPK1 inhibitors.

Authors:  S M Fayaz; G K Rajanikant
Journal:  J Comput Aided Mol Des       Date:  2014-07-01       Impact factor: 3.686

2.  Molecular docking studies on thirteen fluoroquinolines with human topoisomerase II a and b.

Authors:  Ashwini Khanderao Jadhav; Sankunny Mohan Karuppayil
Journal:  In Silico Pharmacol       Date:  2017-06-30

Review 3.  Topoisomerase II as a target for repurposed antibiotics in Candida albicans: an in silico study.

Authors:  Ashwini Khanderao Jadhav; Sankunny Mohan Karuppayil
Journal:  In Silico Pharmacol       Date:  2021-03-26

4.  Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.

Authors:  Malgorzata N Drwal; Jessica Marinello; Stefano G Manzo; Laurence P G Wakelin; Giovanni Capranico; Renate Griffith
Journal:  PLoS One       Date:  2014-12-09       Impact factor: 3.240

5.  Inhibition of DNA-Topoisomerase I by Acylated Triterpene Saponins from Pittosporum angustifolium Lodd.

Authors:  Christian Bäcker; Malgorzata N Drwal; Robert Preissner; Ulrike Lindequist
Journal:  Nat Prod Bioprospect       Date:  2016-01-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.